Search Results - "VUPPALANCHI, Raj"

Therapeutic pipeline in nonalcoholic steatohepatitis by Vuppalanchi, Raj, Noureddin, Mazen, Alkhouri, Naim, Sanyal, Arun J.

“…Our understanding of nonalcoholic fatty liver disease pathophysiology continues to advance rapidly. Accordingly, the field has moved from describing the…”
Get full text

Drug-Induced Liver Injury by Fisher, Kurt, Vuppalanchi, Raj, Saxena, Romil

“…Drug-induced liver injury (DILI) represents a diverse set of responses following exposure to any manufactured or naturally occurring chemical compound…”
Get full text

Significant Dose-Response Association of Physical Activity and Diet Quality with Mortality in Adults with Suspected NAFLD in a Population Study by Vilar-Gomez, Eduardo, Vuppalanchi, Raj, Gawrieh, Samer, Pike, Francis, Samala, Niharika, Chalasani, Naga

“…We aimed to determine whether higher levels (volume and intensity) of physical activity (PA) and diet quality (DQ) are associated with better survival rates in…”
Get full text

Performance characteristics of vibration‐controlled transient elastography for evaluation of nonalcoholic fatty liver disease by Vuppalanchi, Raj, Siddiqui, Mohammad S., Van Natta, Mark L., Hallinan, Erin, Brandman, Danielle, Kowdley, Kris, Neuschwander‐Tetri, Brent A., Loomba, Rohit, Dasarathy, Srinivas, Abdelmalek, Manal, Doo, Edward, Tonascia, James A., Kleiner, David E., Sanyal, Arun J., Chalasani, Naga

“…Vibration‐controlled transient elastography estimates liver stiffness measurement (LSM) and controlled attenuation parameter (CAP), which are noninvasive…”
Get full text

Treatment of acute portal vein thrombosis by nontraditional anticoagulation by Martinez, Melissa, Tandra, Anand, Vuppalanchi, Raj

Get full text

S1432 How Common Is Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease in Patients With Primary Biliary Cholangitis by Ranginani, Dheeksha, Williams, Elizabeth E., Mladenovic, Andrea, Vuppalanchi, Raj K.

Get full text

Liver injury from herbals and dietary supplements in the U.S. Drug‐Induced Liver Injury Network by Navarro, Victor J., Barnhart, Huiman, Bonkovsky, Herbert L., Davern, Timothy, Fontana, Robert J., Grant, Lafaine, Reddy, K. Rajender, Seeff, Leonard B., Serrano, Jose, Sherker, Averell H., Stolz, Andrew, Talwalkar, Jayant, Vega, Maricruz, Vuppalanchi, Raj

“…The Drug‐Induced Liver Injury Network (DILIN) studies hepatotoxicity caused by conventional medications as well as herbals and dietary supplements (HDS). To…”
Get full text

Endoscopic Sedation in Roux-en-Y Gastric Bypass by Vuppalanchi, Raj, MD

Get full text

S1238 Strategy of Combined ICD Codes and MELD Score Yields High Prevalence of Individuals With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis That Are Eligible for Clinical Trials by Kapil, Sasha R., Desai, Archita P., Smith, Anna, Adams, Heather, Vuppalanchi, Raj

Get full text

S1670 A Recent Epidemiologic Shift in Herbal and Dietary Supplement-Induced Liver Injury: Two Decades of Experience From the US Drug-Induced Liver Injury Network by Halegoua-DeMarzio, Dina, Navarro, Victor, Barnhart, Huiman, Bonkovsky, Herb L., Fontana, Robert, Hayashi, Paul, Koh, Christopher, Likhitsup, Alisa, Serrano, Jose, Stolz, Andrew, Vuppalanchi, Raj

Get full text

HLA‐B35:01 and Green Tea–Induced Liver Injury by Hoofnagle, Jay H., Bonkovsky, Herbert L., Phillips, Elizabeth J., Li, Yi‐Ju, Ahmad, Jawad, Barnhart, Huiman, Durazo, Francisco, Fontana, Robert J., Gu, Jiezhun, Khan, Ikhlas, Kleiner, David E., Koh, Christopher, Rockey, Don C., Seeff, Leonard B., Serrano, Jose, Stolz, Andrew, Tillmann, Hans L., Vuppalanchi, Raj, Navarro, Victor J.

“…Background and Aims Herbal supplements, and particularly multi‐ingredient products, have become increasingly common causes of acute liver injury. Green tea is…”
Get full text

Presence and significance of microvesicular steatosis in nonalcoholic fatty liver disease by Tandra, Sweta, Yeh, Matthew M, Brunt, Elizabeth M, Vuppalanchi, Raj, Cummings, Oscar W, Ünalp-Arida, Aynur, Wilson, Laura A, Chalasani, Naga

“…Background & Aims Liver biopsies from patients with nonalcoholic fatty liver disease (NAFLD) sometimes exhibit non-zonal aggregates of hepatocytes with…”
Get full text

S1102 Prevalence of Clinically Significant Steatotic Liver Disease in Inflammatory Bowel Disease: A Prospective Evaluation Using Vibration Controlled Transient Elastography by Pamidimukkala, Ujwala, Ceh, Justin, Williams, Elizabeth E., Peterson, Tonika, Drenzyk, Debbie, Brennan, Sarah Pardue, Leonard, Rebecca A., Fischer, Monika, Bohm, Matthew, Vuppalanchi, Raj, Chalasani, Naga, Sagi, Sashidhar

Get full text

Application of the Latest Advances in Evidence-Based Medicine in Primary Biliary Cholangitis by Kowdley, Kris V., Bowlus, Christopher L., Levy, Cynthia, Mayo, Marlyn J., Pratt, Daniel S., Vuppalanchi, Raj, Younossi, Zobair M.

“…Primary biliary cholangitis (PBC) is a chronic, cholestatic, autoimmune liver disease that can progress to end-stage liver disease and its complications. A…”
Get full text

ERAP-1 and ERAP-2 Variants in Liver Injury After COVID-19 mRNA Vaccination: A US Multicenter Study by Fontana, Robert J, Li, Yi Ju, Vuppalanchi, Raj, Kleiner, David E, Gu, Jiezhun, Shroff, Hersh, Van Wagner, Lisa B, Watkins, Paul B

“…The aim of this study is to describe the presenting features, genetic factors, and outcomes of 23 adults who developed liver injury after coronavirus disease…”
Get full text

Automated quantification and architectural pattern detection of hepatic fibrosis in NAFLD by Gawrieh, Samer, Sethunath, Deepak, Cummings, Oscar W., Kleiner, David E., Vuppalanchi, Raj, Chalasani, Naga, Tuceryan, Mihran

“…Accurate detection and quantification of hepatic fibrosis remain essential for assessing the severity of non-alcoholic fatty liver disease (NAFLD) and its…”
Get full text

Quantitative Prediction of CYP3A4‐ and CYP3A5‐Mediated Drug Interactions by Guo, Yingying, Lucksiri, Aroonrut, Dickinson, Gemma L., Vuppalanchi, Raj K., Hilligoss, Janna K., Hall, Stephen D.

“…We verified a physiologically‐based pharmacokinetic (PBPK) model to predict cytochrome P450 3A4/5‐mediated drug‐drug interactions (DDIs). A midazolam…”
Get full text

Thirty-Day Readmissions Are Largely Not Preventable in Patients With Cirrhosis by Orman, Eric S, Desai, Archita P, Ghabril, Marwan S, Nephew, Lauren D, Patidar, Kavish R, Holden, John, Samala, Niharika R, Gawrieh, Samer, Vuppalanchi, Raj, Sozio, Margaret, Lacerda, Marco, Vilar-Gomez, Eduardo, Lammert, Craig, Liangpunsakul, Suthat, Crabb, David, Masuoka, Howard, Dakhoul, Lara, Pan, Minmin, Gao, Sujuan, Chalasani, Naga

“…Hospital readmissions are common in patients with cirrhosis, but there are few studies describing readmission preventability. We aimed to describe the…”
Get full text

Quantitative assessment of disease severity of primary sclerosing cholangitis with T1 mapping and extracellular volume imaging by Evrimler, Sehnaz, Swensson, Jordan K., Are, Vijay S., Tirkes, Temel, Vuppalanchi, Raj, Akisik, Fatih

“…Purpose Assess the relationship between liver T1 relaxation time and extracellular volume (ECV) fraction and the disease severity of primary sclerosing…”
Get full text

Incidence and Predictors of 30-Day Readmission Among Patients Hospitalized for Advanced Liver Disease by Berman, Kenneth, Tandra, Sweta, Forssell, Kate, Vuppalanchi, Raj, Burton, James R, Nguyen, James, Mullis, Devonne, Kwo, Paul, Chalasani, Naga

“…Background & Aims The rate of readmission to the hospital 30 days after discharge (30-day readmission rate) is used as a quality measure for hospitalized…”
Get full text